| Name | JNJ-1661010 |
| Description | JNJ-1661010 (Takeda-25) is an effective and specific FAAH inhibitor (IC50: 10/ 12 nM for rat/human), shows >100-fold selectivity for FAAH-1 than FAAH-2. |
| In vitro | Preincubation of JNJ-1661010 with fatty acid amide hydrolase showed a slow reversible interaction between JNJ-1661010 and the active site, which was catalyzed by high temperature. In the hydrophobic channel, JNJ-1661010 could dock with phenylthiadiazole, and in the hydrophilic pocket of fatty acid amide hydrolase, it docked with phenylurea. |
| In vivo | Preincubation of JNJ-1661010 with fatty acid amide hydrolase showed a slow reversible interaction between JNJ-1661010 and the active site, which was catalyzed by high temperature. In the hydrophobic channel, JNJ-1661010 could dock with phenylthiadiazole, and in the hydrophilic pocket of fatty acid amide hydrolase, it docked with phenylurea. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 3.7 mg/mL (10.12 mM), Sonication is recommended. DMSO : 36.6 mg/mL (100.15 mM), Sonication is recommended.
|
| Keywords | Takeda25 | Takeda 25 | JNJ-1661010 | Inhibitor | inhibit | hydrolase | Fatty acid amide hydrolase | Fatty | FAAH (rat) | FAAH (human) | FAAH | broad-spectrum | blood-brain | barrier | analgesics | amide | acid |
| Inhibitors Related | WWL 154 | VU534 | Biochanin A | 2-Chlorophenylboronic acid | AA38-3 | Carprofen | Dual FAAH/sEH-IN-1 | FAAH inhibitor 1 | PDP-EA | PF 750 | MM-433593 | JNJ-42165279 |
| Related Compound Libraries | Highly Selective Inhibitor Library | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Anti-Obesity Compound Library | Inhibitor Library | Metabolism Compound Library | Lipid Metabolism Compound Library | Bioactive Compounds Library Max | Preclinical Compound Library | Anti-Metabolism Disease Compound Library |